CDK4 and neoplasm: More importantly, a combination with small-molecule inhibitors of CDK4/6 (palbociclib, abemaciclib, or ribociclib), PI3K (alpelisib or inavolisib), or mTOR (everolimus) produced robust tumor regressions in most cases [121].